StoxPoly Medicure vs Concord Biotech: share price & financials comparison
NSE: POLYMED vs CONCORDBIO · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Poly Medicure vs Concord Biotech at a glance
Poly Medicure (POLYMED) has a market capitalisation of ₹16,342 Cr, against ₹6,618 Cr for Concord Biotech (CONCORDBIO). Over the past year Concord Biotech has returned -12.9%, compared with -18.1% for Poly Medicure. On valuation, Concord Biotech trades at a lower P/E of 23.4 versus 51.3. Concord Biotech earns a higher return on equity (13.6% vs 9.8%). Poly Medicure comes out ahead on size, growth and technicals. Concord Biotech comes out ahead on valuation and profitability. Across the scored metrics below, Poly Medicure leads on 6 and Concord Biotech on 9. On StoxGud's 10-point checklist, Poly Medicure scores 6/10 and Concord Biotech scores 6/10.
| Metric | Poly Medicure | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹16,342 Cr | ₹6,618 Cr |
| Revenue (latest FY) | ₹1,875 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹322 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 51.3 | 23.4 |
| P/B | 5.00 | 3.19 |
| Dividend yield | 0.22% | 1.69% |
| Profitability | ||
| Return on equity | 9.8% | 13.6% |
| Net profit margin | 14.9% | 24.1% |
| Operating margin | 22.7% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | +30.8% | +25.1% |
| Net profit growth (YoY) | +3.6% | +11.1% |
| Revenue CAGR (multi-year) | +19.0% | +1.8% |
| Financial health | ||
| Debt to equity | 0.12 | 0.00 |
| Momentum | ||
| 1-month return | -0.2% | -7.0% |
| 1-year return | -18.1% | -12.9% |
| 3-year CAGR | +5.5% | +3.6% |
| 5-year CAGR | +12.2% | — |
| 10-year CAGR | +23.6% | — |
| Distance from 52W high | -21.9% | -20.3% |
| Technicals | ||
| RSI (14) | 52 | 45 |
| Price vs 200-day avg | +4.3% | -0.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Poly Medicure | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Poly Medicure or Concord Biotech?
Poly Medicure has a market cap of ₹16,342 Cr and Concord Biotech has a market cap of ₹6,618 Cr as of 06 Nov 2026.
Which has a lower P/E, Poly Medicure or Concord Biotech?
Concord Biotech has the lower P/E: Poly Medicure trades at 51.3 and Concord Biotech at 23.4.
Which gave better returns in the last year, Poly Medicure or Concord Biotech?
Concord Biotech did better: Poly Medicure returned -18.1% and Concord Biotech returned -12.9% over one year.
Is Poly Medicure or Concord Biotech a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Poly Medicure scores 6/10 and Concord Biotech scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.